Dashboard
1
With a fall in Net Sales of -16.43%, the company declared Very Negative results in Mar 25
- The company has declared negative results for the last 2 consecutive quarters
- NET SALES(Q) At CNY 4,336.62 MM has Fallen at -29.55%
- INTEREST COVERAGE RATIO(Q) Lowest at 2,486.81
- PRE-TAX PROFIT(Q) At CNY 706.97 MM has Fallen at -53.16%
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 43,293 Million (Large Cap)
19.00
NA
2.60%
-0.15
9.45%
1.83
Revenue and Profits:
Net Sales:
4,625 Million
(Quarterly Results - Jun 2025)
Net Profit:
454 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.22%
0%
-16.22%
6 Months
-10.73%
0%
-10.73%
1 Year
-1.13%
0%
-1.13%
2 Years
19.99%
0%
19.99%
3 Years
43.28%
0%
43.28%
4 Years
77.7%
0%
77.7%
5 Years
60.55%
0%
60.55%
Sichuan Kelun Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.36%
EBIT Growth (5y)
21.45%
EBIT to Interest (avg)
9.46
Debt to EBITDA (avg)
1.25
Net Debt to Equity (avg)
-0.08
Sales to Capital Employed (avg)
0.78
Tax Ratio
22.04%
Dividend Payout Ratio
41.02%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.99%
ROE (avg)
10.61%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.83
EV to EBIT
16.11
EV to EBITDA
10.34
EV to Capital Employed
1.98
EV to Sales
2.11
PEG Ratio
NA
Dividend Yield
2.60%
ROCE (Latest)
12.26%
ROE (Latest)
9.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
4,625.20
5,534.30
-16.43%
Operating Profit (PBDIT) excl Other Income
894.50
1,414.80
-36.78%
Interest
27.20
41.90
-35.08%
Exceptional Items
7.50
2.50
200.00%
Consolidate Net Profit
454.30
930.00
-51.15%
Operating Profit Margin (Excl OI)
117.10%
199.00%
-8.19%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -16.43% vs 9.78% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -51.15% vs 49.59% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
21,536.20
21,151.20
1.82%
Operating Profit (PBDIT) excl Other Income
5,141.30
4,537.70
13.30%
Interest
154.70
370.70
-58.27%
Exceptional Items
-24.50
-39.30
37.66%
Consolidate Net Profit
3,362.00
2,646.60
27.03%
Operating Profit Margin (Excl OI)
178.40%
155.00%
2.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.82% vs 12.58% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 27.03% vs 55.30% in Dec 2023
About Sichuan Kelun Pharmaceutical Co., Ltd. 
Sichuan Kelun Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






